Loading...
XNYS
BLCO
Market cap5.96bUSD
Jul 09, Last price  
16.73USD
1D
0.42%
1Q
1.46%
IPO
-7.06%
Name

Bausch + Lomb Corp

Chart & Performance

D1W1MN
XNYS:BLCO chart
P/E
P/S
1.17
EPS
Div Yield, %
Shrs. gr., 5y
0.22%
Rev. gr., 5y
8.38%
Revenues
5.10b
+6.47%
3,665,000,0003,778,000,0003,412,000,0003,765,000,0003,768,000,0004,146,000,0004,791,000,0005,101,000,000
Net income
-360m
L+13.56%
710,000,000298,000,000-18,000,000182,000,0006,000,000-260,000,000-317,000,000-360,000,000
CFO
283m
+21.98%
763,000,000799,000,000522,000,000873,000,000345,000,000-17,000,000232,000,000283,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bausch + Lomb Corporation is a global leader in eye health, delivering a wide range of products and services across the world. Its business is divided into three key areas: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care sector offers an extensive selection of contact lenses, covering options from daily disposables to frequently replaced types, in addition to lens care solutions, non-prescription eye drops, and vitamin and mineral supplements designed to alleviate conditions such as eye allergies, conjunctivitis, and dry eye. Within the Ophthalmic Pharmaceuticals division, the company develops and markets both proprietary and generic medications for post-operative recovery and the management of ophthalmic conditions like glaucoma, ocular hypertension, and retinal diseases, alongside therapeutic contact lenses. Finally, the Surgical segment equips medical professionals with advanced tools and technologies for cataract, vitreous, and retinal treatments, including intraocular lenses with their specialized delivery systems, phacoemulsification apparatus, and other essential surgical instruments. Founded in 1853, Bausch + Lomb's headquarters are situated in Vaughan, Canada.
IPO date
May 06, 2022
Employees
13,000
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT